Fischer S - Search Results

1

Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients.

Pistrosch F, Herbrig K, Kindel B, Passauer J, Fischer S, Gross P. Pistrosch F, et al. Among authors: fischer s. Diabetes. 2005 Jul;54(7):2206-11. doi: 10.2337/diabetes.54.7.2206. Diabetes. 2005. PMID: 15983223 Clinical Trial.

2

In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control.

Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P. Pistrosch F, et al. Among authors: fischer s. Diabetes Care. 2004 Feb;27(2):484-90. doi: 10.2337/diacare.27.2.484. Diabetes Care. 2004. PMID: 14747233 Clinical Trial.

3

PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells.

Pistrosch F, Herbrig K, Oelschlaegel U, Richter S, Passauer J, Fischer S, Gross P. Pistrosch F, et al. Among authors: fischer s. Atherosclerosis. 2005 Nov;183(1):163-7. doi: 10.1016/j.atherosclerosis.2005.03.039. Atherosclerosis. 2005. PMID: 15907852

4

A single lipid apheresis does not modulate pulse wave reflection in hypercholesterolemic patients.

Passauer J, Herbrig K, Fischer S, Bornstein S, Julius U. Passauer J, et al. Among authors: fischer s. Atheroscler Suppl. 2009 Dec 29;10(5):44-8. doi: 10.1016/S1567-5688(09)71809-4. Atheroscler Suppl. 2009. PMID: 20129373

5

The Dresden Apheresis Center - experience with LDL apheresis and immunoadsorption.

Julius U, Tselmin S, Fischer S, Passauer J, Bornstein SR. Julius U, et al. Among authors: fischer s. Atheroscler Suppl. 2009 Dec 29;10(5):12-6. doi: 10.1016/S1567-5688(09)71803-3. Atheroscler Suppl. 2009. PMID: 20129367

6

Why an apheresis center should offer more than one lipoprotein apheresis method.

Julius U, Fischer S, Schatz U, Passauer J, Bornstein S. Julius U, et al. Among authors: fischer s. Ther Apher Dial. 2013 Apr;17(2):179-84. doi: 10.1111/j.1744-9987.2012.01129.x. Epub 2012 Oct 12. Ther Apher Dial. 2013. PMID: 23551674

7

Insulin resistance and metabolic parameters in type 2 diabetic patients.

Metzler W, Fischer S, Köhler C, Pistrosch F, Kindel B, Hanefeld M. Metzler W, et al. Among authors: fischer s. Eur J Intern Med. 2002 Mar;13(2):108-114. doi: 10.1016/s0953-6205(01)00202-3. Eur J Intern Med. 2002. PMID: 11893468

8

Factors inducing cardiovascular events in patients treated by lipoprotein apheresis.

Taseva K, Fischer S, Passauer J, Weiss N, Bornstein SR, Julius U. Taseva K, et al. Among authors: fischer s. Atheroscler Suppl. 2013 Jan;14(1):45-50. doi: 10.1016/j.atherosclerosissup.2012.10.004. Atheroscler Suppl. 2013. PMID: 23357140

9

Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients.

Fischer S, Patzak A, Rietzsch H, Schwanebeck U, Köhler C, Wildbrett J, Fuecker K, Temelkova-Kurktschiev T, Hanefeld M. Fischer S, et al. Diabetes Obes Metab. 2003 Jan;5(1):38-44. doi: 10.1046/j.1463-1326.2003.00239.x. Diabetes Obes Metab. 2003. PMID: 12542723 Clinical Trial.

10

Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern.

von Dryander M, Fischer S, Passauer J, Müller G, Bornstein SR, Julius U. von Dryander M, et al. Among authors: fischer s. Atheroscler Suppl. 2013 Jan;14(1):39-44. doi: 10.1016/j.atherosclerosissup.2012.10.005. Atheroscler Suppl. 2013. PMID: 23357139

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,768 results

Search Page

Filters